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Abstract
Background: The current CONSORT guidelines for reporting pilot trials do not recommend hypothesis testing of
clinical outcomes on the basis that a pilot trial is under-powered to detect such differences and this is the aim of
the main trial. It states that primary evaluation should focus on descriptive analysis of feasibility/process outcomes
(e.g. recruitment, adherence, treatment fidelity). Whilst the argument for not testing clinical outcomes is justifiable,
the same does not necessarily apply to feasibility/process outcomes, where differences may be large and
detectable with small samples. Moreover, there remains much ambiguity around sample size for pilot trials.
Methods: Many pilot trials adopt a ‘traffic light’ system for evaluating progression to the main trial determined by a
set of criteria set up a priori. We construct a hypothesis testing approach for binary feasibility outcomes focused
around this system that tests against being in the RED zone (unacceptable outcome) based on an expectation of
being in the GREEN zone (acceptable outcome) and choose the sample size to give high power to reject being in
the RED zone if the GREEN zone holds true. Pilot point estimates falling in the RED zone will be statistically non-
significant and in the GREEN zone will be significant; the AMBER zone designates potentially acceptable outcome
and statistical tests may be significant or non-significant.
Results: For example, in relation to treatment fidelity, if we assume the upper boundary of the RED zone is 50% and the
lower boundary of the GREEN zone is 75% (designating unacceptable and acceptable treatment fidelity, respectively), the
sample size required for analysis given 90% power and one-sided 5% alpha would be around n = 34 (intervention group
alone). Observed treatment fidelity in the range of 0–17 participants (0–50%) will fall into the RED zone and be statistically
non-significant, 18–25 (51–74%) fall into AMBER and may or may not be significant and 26–34 (75–100%) fall into GREEN
and will be significant indicating acceptable fidelity.
Discussion: In general, several key process outcomes are assessed for progression to a main trial; a composite approach
would require appraising the rules of progression across all these outcomes. This methodology provides a formal framework
for hypothesis testing and sample size indication around process outcome evaluation for pilot RCTs.
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Background
The importance and need for pilot and feasibility studies
is clear: “A well-conducted pilot study, giving a clear list
of aims and objectives … will encourage methodological
rigour … and will lead to higher quality RCTs” [1]. The
CONSORT extension to external pilot and feasibility tri-
als was published in 2016 [2] with the following key
methodological recommendations: (i) investigate areas of
uncertainty about the future definitive RCT; (ii) ensure
primary aims/objectives are about feasibility, which
should guide the methodology used; (iii) include assess-
ments to address the feasibility objectives which should
be the main focus of data collection and analysis; and
(iv) build decision processes into the pilot design
whether or how to proceed to the main study. Given
that many trials incur process problems during imple-
mentation—particularly with regard to recruitment [3–
5]—the need for pilot and feasibility studies is evident.
One aspect of pilot and feasibility studies that remains
unclear is the required sample size. There is no consen-
sus but recommendations vary from 10 to 12 per group
through to 60–75 per group depending on the main ob-
jective of the study. Sample size may be based on preci-
sion of a feasibility parameter [6, 7]; precision of a
clinical parameter which may inform main trial sample
size—particularly the standard deviation (SD) [8–11] but
also event rate [12] and effect size [13, 14]; or, to a lesser
degree, for clinical scale evaluation [9, 15]. Billingham
et al. [16] reported that the median sample size of pilot
and feasibility studies is around 30–36 per group but
there is wide variation. Herbert et al. [17] reported that
targets within internal as opposed to external pilots are
often slightly larger and somewhat different, being based
on percentages of the total sample size and timeline ra-
ther than any fixed sample requirement.
The need for a clear directive on sample size of studies
is of upmost relevance. The CONSORT extension [2] re-
ports that “Pilot size should be based on feasibility objec-
tives and some rationale given” and states that a
“confidence interval approach may be used to calculate
and justify the sample size based on key feasibility objec-
tive(s)”. Specifically, item 7a (How sample size was de-
termined: Rationale for numbers in the pilot trial)
qualifies: “Many pilot trials have key objectives related to
estimating rates of acceptance, recruitment, retention, or
uptake … for these sorts of objectives, numbers required
in the study should ideally be set to ensure a desired de-
gree of precision around the estimated rate”. Item 7b
(When applicable, explanation of any interim analyses
and stopping guidelines) is generally an uncommon sce-
nario for pilot and feasibility studies and is not given
consideration here.
A key aspect of pilot and feasibility studies is to inform
progression to the main trial, which has important
implications for all key stakeholders (funders, re-
searchers, clinicians and patients). The CONSORT ex-
tension [2] states that “decision processes about how to
proceed needs to be built into the pilot design (which
might involve formal progression criteria to decide
whether to proceed, proceed with amendments, or not
to proceed)” and authors should present “if applicable,
the pre-specified criteria used to judge whether or how
to proceed with a future definitive RCT; … implications
for progression from pilot to future definitive RCT, in-
cluding any proposed amendments”. Avery et al. [18]
published recommendations for internal pilots empha-
sising a traffic light (stop-amend-go/red-amber-green)
approach to progression with focus on process assess-
ment (recruitment, protocol adherence, follow-up) and
transparent reporting around the choice of trial design
and the decision-making processes for stopping, amend-
ing or proceeding to a main trial. The review of Herbert
et al. [17] reported that the use of progression criteria
(including recruitment rate) and traffic light stop-
amend-go as opposed to simple stop-go is increasing for
internal pilot studies.
A common misuse of pilot and feasibility studies has
been the application of hypothesis testing for clinical
outcomes in small under-powered studies. Arain et al.
[19] claimed that pilot studies were often poorly re-
ported with inappropriate emphasis on hypothesis test-
ing. They reviewed 54 pilot and feasibility studies
published in 2007–2008, of which 81% incorporated hy-
pothesis testing of clinical outcomes. Similarly, Leon
et al. [20] stated that a pilot is not a hypothesis testing
study: safety, efficacy and effectiveness should not be
evaluated. Despite this, hypothesis testing has been com-
monly performed for clinical effectiveness/efficacy with-
out reasonable justification. Horne et al. [21] reviewed
31 pilot trials published in physical therapy journals be-
tween 2012 and 2015 and found that only 4/31 (13%)
carried out a valid sample size calculation on effective-
ness/efficacy outcomes but 26/31 (84%) used hypothesis
testing. Wilson et al. [22] acknowledged a number of
statistical challenges in assessing potential efficacy of
complex interventions in pilot and feasibility studies.
The CONSORT extension [2] re-affirmed many re-
searchers’ views that formal hypothesis testing for effect-
iveness/efficacy is not recommended in pilot/feasibility
studies since they are under-powered to do so. Sim’s
commentary [23] further contests such testing of clinical
outcomes stating that treatment effects calculated from
pilot or feasibility studies should not be the basis of a
sample size calculation for a main trial.
However, when the focus of analysis is on confidence
interval estimation for process outcomes, this does not
give a definitive basis for acceptance/rejection of pro-
gression criteria linked to formal powering. The issue in
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this regard is that precision focuses on alpha (α, type I
error) without clear consideration of beta (β, type II
error) and may therefore not reasonably capture true dif-
ferences if a study is under-powered. Further, it could be
argued that hypothesis testing of feasibility outcomes (as
well as addressing both alpha and beta) is justified on
the grounds that moderate-to-large differences (‘process-
effects’) may be expected rather than small differences
that would require large sample numbers. Moore et al.
[24] previously stated that some pilot studies require hy-
pothesis testing to guide decisions about whether larger
subsequent studies can be undertaken, giving the follow-
ing example of how this could be done for feasibility
outcomes: asking the question “Is taste of dietary supple-
ment acceptable to at least 95% of the target popula-
tion?”, they showed that sample sizes of 30, 50 and 70
provide 48%, 78% and 84% power to reject an accept-
ance rate of 85% or lower if the true acceptance rate is
95% using a 1-sided α = 0.05 binomial test. Schoenfeld
[25] advocates that, even for clinical outcomes, there
may be a place for testing at the level of clinical ‘indica-
tion’ rather than ‘clinical evidence’. He suggested that
preliminary hypothesis testing for efficacy could be con-
ducted with high alpha (up to 0.25), not to provide de-
finitive evidence but as an indication as to whether a
larger study should be conducted. Lee et al. [14] also re-
ported how type 1 error levels other than the traditional
5% could be considered to provide preliminary evidence
for efficacy, although they did stop short of recommend-
ing doing this by concluding that a confidence interval
approach is preferable.
Current recommendations for sample sizes of pilot/
feasibility studies vary, have a single rather than a multi-
criterion basis, and do not necessarily link directly to
formal progression criteria. The purpose of this article is
to introduce a simple methodology that allows sample
size derivation and formal testing of proposed progres-
sion cut-offs, whilst offering suggestions for multi-
criterion assessment, thereby giving clear guidance and
sign-posting for researchers embarking on a pilot/feasi-
bility study to assess uncertainty in feasibility parameters
prior to a main trial. The suggestions within the article
do not directly apply to internal pilot studies built into
the design of a main trial, but given the similarities to
external randomised pilot and feasibility studies, many
of the principles outlined here for external pilots might
also extend to some degree to internal pilots of rando-
mised and non-randomised studies.
Methods
The proposed approach focuses on estimation and hy-
pothesis testing of progression criteria for feasibility out-
comes that are potentially modifiable (e.g. recruitment,
treatment fidelity/ adherence, level of follow up). Thus,
it aligns with the main aims and objectives of pilot and
feasibility studies and with the progression stop-amend-
go recommendations of Eldridge et al. [2] and Avery
et al. [18].
Hypothesis concept
Let RUL denote the upper RED zone cut-off and GLL de-
note the lower GREEN zone cut-off. The concept is to set
up hypothesis testing around progression criteria that tests
against being in the RED zone (designating unacceptable
feasibility—‘STOP’) based on an alternative of being in the
GREEN zone (designating acceptable feasibility—‘GO’).
This is analogous to the zero difference (null) and clinic-
ally important difference (alternative) in a main superiority
trial. Specifically, we are testing against RUL when GLL is
hypothesised to be true:
 Null hypothesis: True feasibility outcome (ε) not
greater than the upper “RED” stop limit (RUL)
 Alternative hypothesis: True feasibility outcome (ε)
is greater than RUL
The test is a 1-tailed test with suggested alpha (α) of
0.05 and beta (β) of 0.05, 0.1 or 0.2, dependent on the
required strength of evidence of the test. An example of
a feasibility outcome might be percentage recruitment
uptake.
Progression rules
Let E denote the observed point estimate (ranging from
0 to 1 for proportions, or for percentages 0–100%). Sim-
ple 3-tiered progression criteria would follow as:
 E ≤ RUL [P value non-significant (P ≥ α)] -> RED
(unacceptable—STOP)
 RUL < E < GLL -> AMBER (potentially
acceptable—AMEND)
 E ≥ GLL [P value significant (P < α)] -> GREEN
(acceptable—GO)
Sample size
Table 1 displays a quick look-up grid for sample size
across a range of anticipated proportions for RUL and
GLL for one-sample one-sided 5% alpha with typical 80%
and 90% (as well as 95%) power for the normal approxi-
mation method with continuity correction (see Appen-
dix for corresponding mathematical expression; derived
from Fleiss et al. [26]). Table 2 is the same look-up grid
relating to the Binomial exact approach with sample
sizes derived using G*Power version 3.1.9.7 [27]. Clearly,
as the difference between proportions RUL and GLL in-
creases the sample size requirement is reduced.
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Table 1 Sample size and significance cut-points for (GLL-RUL) differences for a one-sample test, power (80%, 90%, 95%) and 1-tailed
5% significance level based on normal approximation (with continuity correction)
RUL GLL α (0.05), β (0.2) α (0.05), β (0.1) α (0.05), β (0.05)
% % n Ac (%) n Ac (%) n Ac (%)
10 20 79 12.3 (15.6) 111 16.3 (14.7) 143 20.2 (14.1)
15 25 101 21.1 (20.8) 140 28.0 (20.0) 179 34.7 (19.4)
15 30 49 11.5 (23.4) 68 15.0 (22.1) 87 18.5 (21.3)
20 30 119 31.0 (26.0) 165 41.5 (25.1) 209 51.3 (24.6)
20 35 57 16.4 (28.7) 78 21.4 (27.5) 99 26.3 (26.6)
20 40 34 10.6 (31.3) 46 13.7 (29.7) 59 16.9 (28.6)
25 35 134 41.7 (31.2) 185 55.9 (30.2) 234 69.4 (29.7)
25 40 63 21.4 (34.0) 86 28.1 (32.7) 109 34.7 (31.8)
25 45 37 13.6 (36.7) 51 17.8 (35.0) 64 21.7 (33.9)
25 50 25 9.8 (39.2) 33 12.3 (37.4) 42 15.1 (36.0)
30 40 146 52.9 (36.2) 201 71.0 (35.3) 253 87.9 (34.7)
30 45 68 26.6 (39.1) 93 35.2 (37.8) 117 43.3 (37.0)
30 50 39 16.4 (42.1) 54 21.7 (40.3) 67 26.3 (39.2)
30 55 26 11.6 (44.8) 35 15.0 (42.7) 44 18.2 (41.4)
30 60 18 8.6 (47.8) 25 11.3 (45.1) 30 13.1 (43.8)
35 45 155 64.0 (41.3) 212 85.6 (40.4) 267 106.3 (39.8)
35 50 71 31.5 (44.3) 97 41.7 (43.0) 121 51.0 (42.1)
35 55 41 19.4 (47.3) 56 25.5 (45.5) 69 30.7 (44.4)
35 60 27 13.5 (50.1) 36 17.3 (48.1) 44 20.6 (46.8)
35 65 19 10.1 (53.0) 25 12.7 (50.7) 31 15.2 (49.1)
40 50 160 74.2 (46.4) 219 99.5 (45.4) 275 123.4 (44.9)
40 55 73 36.1 (49.4) 99 47.6 (48.1) 124 58.6 (47.2)
40 60 42 22.0 (52.4) 56 28.4 (50.8) 70 34.7 (49.6)
40 65 27 15.0 (55.5) 36 19.2 (53.4) 44 22.9 (52.1)
40 70 19 11.1 (58.5) 25 14.0 (56.1) 30 16.4 (54.7)
45 55 163 83.8 (51.4) 222 112.1 (50.5) 278 138.7 (49.9)
45 60 74 40.3 (54.5) 100 53.2 (53.2) 124 64.9 (52.3)
45 65 42 24.2 (57.6) 56 31.3 (55.9) 69 37.8 (54.9)
45 70 27 16.4 (60.7) 36 21.1 (58.6) 44 25.2 (57.3)
45 75 19 12.1 (63.8) 24 14.8 (61.7) 29 17.5 (60.2)
50 60 162 91.5 (56.5) 220 122.2 (55.5) 275 151.5 (55.0)
50 65 73 43.5 (59.6) 98 57.1 (58.3) 121 69.5 (57.5)
50 70 41 25.8 (62.8) 55 33.6 (61.1) 67 40.2 (60.0)
50 75 27 17.8 (65.8) 34 21.8 (64.1) 42 26.3 (62.7)
55 65 159 97.8 (61.5) 214 129.7 (60.6) 267 160.2 (60.0)
55 70 71 45.9 (64.7) 94 59.6 (63.4) 117 73.2 (62.6)
55 75 40 27.2 (67.9) 52 34.5 (66.3) 64 41.7 (65.2)
60 70 152 101.1 (66.5) 204 133.9 (65.6) 253 164.6 (65.1)
60 75 68 47.4 (69.8) 89 61.0 (68.5) 109 73.8 (67.7)
60 80 38 27.8 (73.1) 48 34.4 (71.6) 59 41.6 (70.5)
65 75 142 101.6 (71.6) 189 133.6 (70.7) 234 164.1 (70.1)
65 80 63 47.2 (74.9) 81 59.7 (73.7) 99 72.2 (72.9)
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Multi-criteria assessment
We recommend that progression for all key feasibility
criteria should be considered separately, and hence over-
all progression would be determined by the worst-
performing criterion, e.g. RED if at least one signal is
RED, AMBER if none of the signals fall into RED but at
least one falls into AMBER and GREEN if all signals fall
into the GREEN zone. Hence, the GREEN signal to ‘GO’
across the set of individual criteria will give indication
that progression to a main trial can take place without
any necessary changes. A signal to ‘STOP’ and not
proceed to a main trial is recommended if any of the ob-
served estimates are ‘unacceptably’ low (i.e. fall within
the RED zone). Otherwise, where neither ‘GO’ nor
‘STOP’ are signalled, the design of the trial will need
amending by indication of subpar performance on one
or more of the criteria.
Sample size requirements across multi-criteria will
vary according to the designated parameters linked to
the progression criteria, which may be set at different
stages of the study on different numbers of patients (e.g.
those screened, eligible, recruited and randomised, allo-
cated to the intervention arm, total followed up). The
overall size needed will be dictated by the requirement
to power each of the multi-criteria statistical tests. Since
these tests will yield separate conclusions in regard to
the decision to ‘STOP’, ‘AMEND’ or ‘GO’ across all indi-
vidual feasibility criteria there is no need to consider a
multiple testing correction with respect to alpha. How-
ever, researchers may wish to increase power (and
hence, sample size) to ensure adequate power to detect
‘GO’ signals across the collective set of feasibility criteria.
For example, powering at 90% across three criteria (as-
sumed independent) will ensure a collective power of
73% (i.e. 0.93), which may be considered reasonable, but
80% power across five criteria will reduce the power of
the combined test to 33%. The final three columns of
Table 1 cover the sample sizes required for 95% power,
which may address collective multi-criteria assessment
when considering keeping a high overall statistical
power.
Further expansion of AMBER zone
Within the same sample size framework, the AMBER
zone may be further split to indicate whether ‘minor’ or
‘major’ amendments are required according to the sig-
nificance of the p value. Consider a 2-way split in the
AMBER zone denoted by cut-off AC, which indicates the
threshold for statistical significance, where an observed
estimate below the cut-point will result in a non-
significant result and an estimate at or above the cut-
point a significant result. Let AMBERR denote the region
of Amber zone adjacent to the RED zone between RUL
and AC, and AMBERG denote the region of AMBER
zone between AC and GLL adjacent to the GREEN zone.
This would draw on two possible levels of amendment
(‘major’ AMEND and ‘minor’ AMEND) and the re-
configured approach would follow as:
 E ≤ RUL [P value non-significant (P ≥ α)] -> RED
(unacceptable—STOP)
 RUL < E < GLL -> AMBER (potentially
acceptable—AMEND)
 RUL < E < GLL and P ≥ α {RUL < E < Ac} ->
AMBERR (major AMEND)
 RUL < E < GLL and P < α { Ac ≤ E < GLL} ->
AMBERG (minor AMEND)
 E ≥ GLL [P value significant (P < α)] -> GREEN
(acceptable—GO)
Table 1 Sample size and significance cut-points for (GLL-RUL) differences for a one-sample test, power (80%, 90%, 95%) and 1-tailed
5% significance level based on normal approximation (with continuity correction) (Continued)
RUL GLL α (0.05), β (0.2) α (0.05), β (0.1) α (0.05), β (0.05)
% % n Ac (%) n Ac (%) n Ac (%)
65 85 34 26.7 (78.5) 44 33.8 (76.8) 52 39.5 (75.9)
70 80 129 98.9 (76.6) 170 128.8 (75.8) 209 157.2 (75.2)
70 85 56 44.8 (80.1) 72 56.8 (78.9) 87 67.9 (78.1)
75 85 113 92.3 (81.7) 147 118.9 (80.9) 179 143.8 (80.3)
75 90 48 40.9 (85.3) 60 50.5 (84.2) 71 59.3 (83.5)
80 90 93 80.7 (86.8) 119 102.4 (86.0) 143 122.3 (85.5)
RUL upper limit of RED zone (expressed as percentage of total sample), GLL lower limit of GREEN zone (expressed as percentage of total sample), AC AMBER-
statistical significance threshold (within the AMBER zone) where an observed estimate below the cut-point will result in a non-significant result (p ≥ 0.05) and
figures at or above the cut-point will be significant (p < 0.05) (%, as a percentage of n)
Sample sizes were derived using the normal approximation to the binomial distribution (with continuity correction) formula given in the Appendix, which by
convention is stable for np > 5 and n(1 − p) > 5.
For this approach, AC% is calculated from the 1-sided upper 95% confidence limit for the null proportion: 100% × (RUL + z1−α√((RUL(1 − RUL))/n)) [e.g. for RUL = 20%
v GLL = 35%, n = 78, power 90%: AC% = 100% × (0.2 + 1.645√((0.2(1 − 0.2))/78)) = 27.5%. In the example this is expressed as a proportion (0.275)]
The AC values do not account for the continuity correction (− 0.5 deduction) which would need to be applied to the observed count from a study prior to cross-
checking against the AC cut-offs provided here
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Table 2 Sample size and significance cut-points for (GLL-RUL) differences for a one-sample test, power (80%, 90%, 95%) and 1-tailed
5% significance level based on the binomial exact test
RUL GLL α (0.05), β (0.2) α (0.05), β (0.1) α (0.05), β (0.05)
% % n Ac (%) n Ac (%) n Ac (%)
10 20 78 13 (16.7) 109 17 (15.6) 135 20 (14.8)
15 25 101 22 (21.8) 136 28 (20.6) 176 35 (19.9)
15 30 48 12 (25.0) 64 15 (23.4) 85 19 (22.4)
20 30 116 31 (26.7) 160 41 (25.6) 204 51 (25.0)
20 35 56 17 (30.4) 77 22 (28.6) 98 27 (27.6)
20 40 35 12 (34.3) 47 15 (31.9) 60 18 (30.0)
25 35 129 41 (31.8) 179 55 (30.7) 230 69 (30.0)
25 40 62 22 (35.5) 83 28 (33.7) 107 35 (32.7)
25 45 36 14 (38.9) 49 18 (36.7) 62 22 (35.5)
25 50 26 11 (42.3) 33 13 (39.4) 42 16 (38.1)
30 40 144 53 (36.8) 193 69 (35.8) 248 87 (35.1)
30 45 67 27 (40.3) 93 36 (38.7) 114 43 (37.7)
30 50 39 17 (43.6) 53 22 (41.5) 67 27 (40.3)
30 55 25 12 (48.0) 36 16 (44.4) 44 19 (43.2)
30 60 17 9 (52.9) 25 12 (48.0) 28 13 (46.4)
35 45 148 62 (41.9) 206 84 (40.8) 262 105 (40.1)
35 50 68 31 (45.6) 96 42 (43.8) 119 51 (42.9)
35 55 41 20 (48.8) 53 25 (47.2) 68 31 (45.6)
35 60 26 14 (53.8) 36 18 (50.0) 45 22 (48.9)
35 65 19 11 (57.9) 24 13 (54.2) 29 15 (51.7)
40 50 158 74 (46.8) 214 98 (45.8) 268 121 (45.1)
40 55 71 36 (50.7) 94 46 (48.9) 119 57 (47.9)
40 60 42 23 (54.8) 56 29 (51.8) 67 34 (50.7)
40 65 28 16 (57.1) 34 19 (55.9) 45 24 (53.3)
40 70 19 12 (63.2) 25 15 (60.0) 28 16 (57.1)
45 55 154 80 (51.9) 220 112 (50.9) 269 135 (50.2)
45 60 70 39 (55.7) 98 53 (54.1) 119 63 (52.9)
45 65 42 25 (59.5) 54 31 (57.4) 68 38 (55.9)
45 70 25 16 (64.0) 36 22 (61.1) 44 26 (59.1)
45 75 16 11 (68.8) 23 15 (65.2) 29 18 (62.1)
50 60 158 90 (57.0) 213 119 (55.9) 268 148 (55.2)
50 65 69 42 (60.9) 93 55 (59.1) 119 69 (58.0)
50 70 37 24 (64.9) 53 33 (62.3) 67 41 (61.2)
50 75 23 16 (69.6) 33 22 (66.7) 42 27 (64.3)
55 65 150 93 (62.0) 210 128 (61.0) 262 158 (60.3)
55 70 70 46 (65.7) 92 59 (64.1) 114 72 (63.2)
55 75 37 26 (70.3) 50 34 (68.0) 62 41 (66.1)
60 70 143 96 (67.1) 197 130 (66.0) 248 162 (65.3)
60 75 62 44 (71.0) 85 59 (69.4) 107 73 (68.2)
60 80 36 27 (75.0) 45 33 (73.3) 60 43 (71.7)
65 75 133 96 (72.2) 180 128 (71.1) 230 162 (70.4)
65 80 55 42 (76.4) 75 56 (74.7) 98 72 (73.5)
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In Tables 1 and 2 in relation to designated sample
sizes for different RUL and GLL and specified α and β, we
show the corresponding cut-points for statistical signifi-
cance (p < 0.05) both in absolute terms of sample num-
ber (n) [AC] and as a percentage of the total sample sizes
[AC%].
Results
A motivating example (aligned to the normal approxi-
mation approach) is presented in Table 3, which illus-
trates a pilot trial with three progression criteria. Table 4
presents the sample size calculations for the example
scenario following the 3-tiered approach, and Table 5
gives the sample size calculations for the example sce-
nario using the extended 4-tiered approach. Cut-points
for the feasibility outcomes relating to the shown sample
sizes are also presented to show RED, AMBER and
GREEN zones for each of the three progression criteria.
Overall sample size requirement should be dictated by
the multi-criteria approach. This is illustrated in Table 4
where we have three progression criteria each with a dif-
ferent denominator population. For recruitment uptake,
the denominator denotes the total number of children
screened and the numerator the number of children ran-
domised; for follow-up, the denominator is the number
of children randomised with the numerator being num-
ber of those randomised who are successfully followed
up; and lastly for treatment fidelity, the denominator is
the number allocated to the intervention arm with the
numerator being the number of children who were ad-
ministered the treatment correctly by the dietician. In
the example in order to meet the individual ≥ 90% power
requirement for all three criteria we would need: (i) for
recruitment, the number to be screened to be 78; (ii) for
treatment fidelity, the number in the intervention arm to
be 34; and (iii) for follow up, the number randomised to
be 44. In order to determine the overall sample size for
the whole study, we base our decision on the criterion
that requires the largest numbers, which is the treatment
fidelity criterion which requires 68 to be randomised.
We cannot base our decision on the 78 required to be
screened for recruitment because this would give only
an expected number of 28 randomised (i.e. 35% of 78). If
we expect 35% recruitment uptake, then we need to in-
flate the total 68 (randomised) to be 195 (1/0.35 × 68)
children to be screened (rounded to 200). This would
give 99.9%, 90% and 98.8% power for criteria (i), (ii) and
(iii), respectively (assuming 68 of the 200 screened are
randomised), giving a very reasonable collective 88.8%
power of rejecting the null hypotheses over the three cri-
teria if the alternative hypotheses (for acceptable feasibil-
ity outcomes) are true in each case.
Table 2 Sample size and significance cut-points for (GLL-RUL) differences for a one-sample test, power (80%, 90%, 95%) and 1-tailed
5% significance level based on the binomial exact test (Continued)
RUL GLL α (0.05), β (0.2) α (0.05), β (0.1) α (0.05), β (0.05)
% % n Ac (%) n Ac (%) n Ac (%)
65 85 31 25 (80.6) 42 33 (78.6) 52 40 (76.9)
70 80 119 92 (77.3) 164 125 (76.2) 204 154 (75.5)
70 85 49 40 (81.6) 69 55 (79.7) 85 67 (78.8)
75 85 103 85 (82.5) 139 113 (81.3) 176 142 (80.7)
75 90 45 39 (86.7) 55 47 (85.5) 70 59 (84.3)
80 90 82 72 (87.8) 112 97 (86.6) 135 116 (85.9)
RUL upper limit of RED zone (expressed as percentage of total sample), GLL lower limit of GREEN zone (expressed as percentage of total sample), AC AMBER-
statistical significance threshold (within the AMBER zone) where an observed estimate below the cut-point will result in a non-significant result (p ≥ 0.05) and
figures at or above the cut-point will be significant (p < 0.05) (%, expressed as a percentage of sample size (n))
Table 3 Motivating example—feasibility trial for oral protein
energy supplements as flavoured drinks to improve nutritional
status in children with cystic fibrosis
A feasibility trial is being set up to see whether children aged 2 to 15
years with cystic fibrosis will take oral protein energy supplements as
flavoured drinks to improve their nutritional status, compared to
receiving dietary advice alone. Children are to be randomised in a 1:1
allocation ratio using a parallel two-arm design. The research team
wants to be sure they can meet three feasibility objectives before they
go ahead and plan the main trial: reasonable recruitment uptake, high
treatment fidelity (i.e. extent to which dietician practitioners comply with
the treatment protocol) and adequate retention of children at follow up.
The team asks their senior statistician to help them decide on an appro-
priate methodology including pilot sample size. The statistician suggests
a traffic light approach incorporating hypothesis testing of the feasibility
outcomes.
Together, the team devise three progression criteria that should be met
before the main trial can be considered feasible as follows:
a. At least 35% of the children screened as eligible should be recruited
but the trial will not be feasible if recruitment uptake is 20% or less.
b. A high level of treatment fidelity should be maintained with 75% or
more children being given the correct treatment plan by the dietician,
but if 50% or less children are given the plan as specified in the
protocol then the trial is not feasible.
c. 85% or more of the children should be retained in the study at
follow up, with 65% or less retention indicating that the main trial is not
feasible.
The decision criteria and required sample size around these are detailed
through two possible approaches within Table 4 (simple 3-tier ap-
proach) and Table 5 (extended 4-tier approach). The statistician is to use
the normal approximation method (with continuity correction) for the
sample size calculation and analysis.
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Inherent in our approach are the probabilities around
sample size, power and hypothesised feasibility parame-
ters. For example, taking the cut-offs from treatment fi-
delity as a feasibility outcome from Table 4 (ii), we
set a lower GREEN zone limit of GLL = 0.75 (“accept-
able” (hypothesised alternative value)) and an upper
RED zone limit of RUL = 0.5 (“not acceptable”
(hypothesised null value)) for rejecting the null for
this criterion based on 90% power and a 1-sided 5%
significance level (alpha). Figure 1 presents the nor-
mal probability density functions for ε, for the null
and alternative hypotheses. In the illustration this
would imply through normal sampling theory that if
GLL holds true (i.e. true recruitment uptake (ε) =
GLL) there would be the following:
 A probability of 0.1 (type II error probability β) of the
estimate falling within RED/AMBERR zones (i.e. blue
shaded area under the curve to the left of AC where
the test result will be non-significant (p ≥ 0.05))
Table 4 Case illustration (standard 3-tiered approach)
A two-arm parallel design (1:1 allocation to intervention and control
arms) with three key feasibility objectives, to assess (i) recruitment up-
take (percent of screened patients recruited), (ii) treatment fidelity and
(iii) participant retention (follow up). Hypothesis testing incorporates α
(1-sided) = 5% and power = 90%. The normal approximation method is
used.
Assume the progression criteria (and affiliated sample size requirements)
for each are as follows:
(i) Recruitment uptake ≤ 20% (RED zone) and ≥ 35% (GREEN zone) {RUL
= 20%, GLL = 35%}
→ Required sample size n = 78 [total screened patients]
(ii) Treatment fidelity ≤ 50% (RED zone) and ≥ 75% (GREEN zone) {RUL =
50%, GLL = 75%}
→ Required sample size n = 34 [intervention arm only]
(iii) Follow up: ≤ 65% (RED zone), ≥ 85% (GREEN zone) {RUL = 65%, GLL
= 85%}
→ Required sample size n = 44 (total randomised participants with 22
per arm)
The sample sizes across criteria (i)-(iii) are at different levels—(i) is at the
level of screened patients, whereas (ii)–(iii) are at the level of
randomised patients. To meet criteria (i), we need ns ≥ 78 (although we
will recruit ns = 200 (i.e. (1/0.35) × nr (rounded up to 200)) where 0.35 is
the expected proportion uptake of the total number screened), and for
(ii)–(iii), we need nr = 68 (34 per arm, based on (ii)).
Taking each of the objectives in turn (and the updated sample sizes to
meet the multi-criteria objectives), we express progression criteria for
the three objectives as follows:
(i) Recruitment uptake [required ns ≥ 78; expected ns = 200; maximum
ns = 340 (i.e. (1/0.2)x nr)]
• E ≤ 0.2 [P ≥ 0.05] -> RED (STOP)
• 0.2 < E < 0.35 -> AMBER (AMEND)
• E ≥ 0.35 [P < 0.05] -> GREEN (GO)
Signals for expected ns = 200:
0 to 40 (RED), > 40 to < 70 (AMBER) and 70 to 200 (GREEN) {i.e. 0.2 ×
200 = 40; 0.35 × 200 = 70}
(ii) Treatment fidelity [ni = 34 (intervention arm only)]
• E ≤ 0.5 [P ≥ 0.05] -> RED (STOP)
• 0.5 < E < 0.75 -> AMBER (AMEND)
• E ≥ 0.75 [P < 0.05] -> GREEN (GO)
Signals for ni = 34:
0 to 17 (RED), > 17 to < 25.5 (AMBER) and 25.5 to 34 (GREEN) {i.e. 0.5 ×
34 = 17; 0.75 × 34 = 25.5}
(iii) Follow up [nr = 68 (intervention and control arms)]
• E ≤ 0.65 [P ≥ 0.05] -> RED (STOP)
• 0.65 < E < 0.85 -> AMBER (AMEND)
• E ≥ 0.85 [P < 0.05] -> GREEN (GO)
Signals for nr = 68:
0 to 44.2 (RED), > 44.2 to < 57.8 (AMBER) and 57.8 to 68 (GREEN) {i.e.
0.65 × 68 = 44.2; 0.85 × 68 = 57.8}
[Note: The continuity correction (− 0.5 deduction) needs to be applied
to the observed count from the study for each criterion prior to
assessing into which signal band it falls]
In accordance with the multi-criteria aim, the decision to proceed would
be based on the worst signal
➢ If signal = RED for (i) or (ii) or (iii) -> overall signal is RED
➢ Else, if no signal is RED but signal = AMBER for (i) or (ii) or (iii) ->
overall signal is AMBER
➢ Else, if signals = GREEN for (i) and (ii) and (iii) -> overall signal is
GREEN
RUL upper limit of RED zone, GLL lower limit of GREEN zone, ns number of
screened patients who are eligible to being randomised, nr number of eligible
patients randomised, ni number of patients randomised to the
intervention arm
Table 5 Case illustration (re-visited using 4-tiered approach)
Taking each of the objectives in turn, we re-express the progression cri-
teria for the three objectives according to the 4-tiered approach, as
follows:
(i) Recruitment uptake [expected ns = 200]
• E ≤ 0.2 [P ≥ 0.05] -> RED (STOP)
• 0.2 < E < 0.35 -> AMBER (AMEND)//{Ac = 0.247 (i.e. 0.2 + 1.645√(0.2 ×
0.8/200))}*
o 0.2 < E < 0.247 [P ≥ 0.05] -> AMBERR (AMEND-major)
o 0.247 ≤ E < 0.35 [P < 0.05] -> AMBERG (AMEND-minor)
• E ≥ 0.35 [P < 0.05] -> GREEN (GO)
Signals for ns = 200:
0 to 40 (RED), > 40 to < 49.4 (AMBERR), 49.4 to < 70 (AMBERG) and 70 to
200 (GREEN) {i.e. 0.2 × 200 = 40, 0.247 × 200 = 49.4, 0.35 × 200 = 70}
(ii) Treatment fidelity [ni = 34 (intervention arm only)]
• E ≤ 0.5 [P ≥ 0.05] -> RED (STOP)
• 0.5 < E < 0.75 -> AMBER (AMEND)//{AC = 0.641 (i.e. 0.5 + 1.645√(0.5 ×
0.5/34))—as shown in Table 1}*
o 0.5 < E < 0.641 [P ≥ 0.05] -> AMBERR (AMEND-major)
o 0.641 ≤ E < 0.75 [P < 0.05] -> AMBERG (AMEND-minor)
• E ≥ 0.75 [P < 0.05] -> GREEN (GO)
Signals for ni = 34:
0 to 17 (RED), > 17 to < 21.79 (AMBERR), 21.79 to < 25.5 (AMBERG) and
25.5 to 34 (GREEN) {i.e. 0.5 × 34 = 17, 0.641 × 34 = 21.794, 0.75 × 34 =
25.5}
(iii) Follow up [nr = 68 (intervention and control arms)]
• E ≤ 0.65 [P ≥ 0.05] -> RED (STOP)
• 0.65 < E < 0.85 -> AMBER (AMEND)//{Ac = 0.745 (i.e. 0.65 +
1.645x√(0.65 × 0.35/68))}*
o 0.65 < E < 0.745 [P ≥ 0.05] -> AMBERR (AMEND-major)
o 0.745 ≤ E < 0.85 [P < 0.05] -> AMBERG (AMEND-minor)
• E ≥ 0.85 [P < 0.05] -> GREEN (GO)
Signals for nr = 68:
0 to 44.2 (RED), > 44.2 to < 50.66 (AMBERR), 50.66 to < 57.8 (AMBERG)
and 57.8 to 70 (GREEN) {i.e. 0.65 × 68 = 44.2, 0.745 × 68 = 50.66, 0.85 ×
68 = 57.8}
[Note: The continuity correction (-0.5 deduction) needs to be applied to
the observed count from the study for each criterion prior to assessing
into which signal band it falls]
In accordance with the multi-criteria aim, the decision to proceed would
be based on the worst signal (as in Table 4)
ns number of screened patients who are eligible to being randomised,
nr number of eligible patients randomised, ni number of patients randomised to
the intervention arm
*AC is calculated from the 1-sided upper 95% confidence limit for the null
proportion: RUL + z1−α√((RUL(1 − RUL))/n) where z1−α = 1.645 (for 1-sided 5%
significance test)
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Fig. 1 Illustration of power using the 1-tailed hypothesis testing against the traffic light signalling approach to pilot progression. E, observed point estimate;
RUL, upper limit of RED zone; GLL, lower limit of GREEN zone; Ac, cut-off for statistical significance (at the 1-sided 5% level); α, type I error; β, type II error
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 Probability of 0.4 of it falling in the AMBERG zone
(i.e. area under the curve to the right of AC but
below GLL)
 Probability of 0.5 of the estimate falling in the GREEN
zone (i.e. GLL and above).
If RUL (the null) holds true (i.e. true feasibility outcome
(ε) = RUL), there would be the following:
 A probability of 0.05 (one-tailed type I error
probability α) of the statistic/estimate falling in
the AMBERG/GREEN zones (i.e. pink shaded area
under the curve to the right of AC where the test
result will be significant (p < 0.05) as shown
within Fig. 1)
 Probability of 0.45 of it falling in the AMBERR zone
(i.e. to the left of AC but above RUL)
 Probability of 0.5 of the estimate falling in the RED
zone (i.e. RUL and below)
Figure 1 also illustrates how changing the sample size
affects the sampling distribution and power of the
analysis around the set null value (at RUL) when the
hypothesised alternative (GLL) is true. The figure empha-
sises the need for a large enough sample to safeguard
against under-powering of the pilot analysis (as shown
in the last plot which has a wider bell-shape than the
first two plots and where the size of the beta probability
is increased).
Figure 2 plots the probabilities of making each type of
traffic light decision as functions of the true parameter
value (focused on the recruitment uptake example from
Table 5 (i)). Additional file 1 presents the R code for re-
producing these probabilities and enables readers to in-
sert different parameter values.
Discussion
The methodology introduced in this article provides an
innovative formal framework and approach to sample
size derivation, aligning sample size requirement to pro-
gression criteria with the intention of providing greater
transparency to the progression process and full engage-
ment with the standard aims and objectives of pilot/
feasibility studies. Through the use of both alpha and
Fig. 2 Probability of traffic light given true underlying probability of an event using the example from Table 5 (i). Two plots are presented: a
relating to normal approximation approach and b relating to binomial exact approach. Based on n = 200, RUL = 40 and GLL = 70
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beta parameters (rather than alpha alone), the method
ensures rigour and capacity to address the progression
criteria by ensuring there is adequate power to detect an
acceptable threshold for moving forward to the main
trial. As several key process outcomes are assessed in
parallel and in combination, the method embraces a
composite multi-criterion approach that appraises sig-
nals for progression across all the targeted feasibility
measures. The methodology extends beyond the require-
ment for ‘sample size justification but not necessarily
sample size calculation’ [28].
The focus of the strategy reported here is on process
outcomes, which align with the recommended key objec-
tives of primary feasibility evaluation for pilot and feasi-
bility studies [2, 24] and necessary targets to address key
issues of uncertainty [29]. The concept of justifying pro-
gression is key. Charlesworth et al. [30] developed a
checklist for intended use in decision-making on
whether pilot data could be carried forward to a main
trial. Our approach builds on this philosophy by introdu-
cing a formalised hypothesis test approach to address
the key objectives and pilot sample size. Though the
suggested sample size derivation focuses around the key
process objectives, it may also be the case that other ob-
jectives are also important, e.g. assessment of precision
of clinical outcome parameters. In this case, researchers
may also wish to ensure that the size of the study suit-
ably covers the needs of those evaluations, e.g. to esti-
mate the SD of the intended clinical outcome, then the
overall sample size may be boosted to cover this add-
itional objective [10]. This tallies with the review by
Blatch-Jones et al. [31] who reported that testing recruit-
ment, determining the sample size and numbers avail-
able, and the intervention feasibility were the most
commonly used targets of pilot evaluations.
Hypothesis testing in pilot studies, particularly in the
context of effectiveness/efficacy of clinical outcomes, has
been widely criticised due to the improper purpose and
lack of statistical power of such evaluations [2, 20, 21,
23]. Hence, pilot evaluations of clinical outcomes are not
expected to include hypothesis testing. Since the main
focus is on feasibility the scope of the testing reported
here is different and importantly relates back to the rec-
ommended objectives of the study whilst also aligning
with nominated progression criteria [2]. Hence, there is
clear justification for this approach. Further, for the sim-
ple 3-tiered approach hypothesis testing is somewhat
hypothetical: there is no need to physically carry out a
test since the zonal positioning of the observed sample
statistic estimate for the feasibility outcome will deter-
mine the decision in regard to progression; thus adding
to the simplicity of the approach.
The link between the sample size and need to ad-
equately power the study to detect a meaningful
feasibility outcome gives this approach the extra rigour
over the confidence interval approach. It is this sample
size-power linkage that is key to the determination of
the respective probabilities of falling into the different
zones and is a fundamental underpinning to the meth-
odological approach. In the same way as for a key clin-
ical outcome in a main trial where the emphasis is not
just on alpha but also on beta thereby addressing the
capacity to detect a clinically significant difference, simi-
larly, our approach is to ensure there is sufficient cap-
acity to detect a meaningful signal for progression to a
main trial if it truly exists. A statistically significant find-
ing in this context will at least provide evidence to reject
RED (signifying a decision to STOP) and in the 4-tiered
case it would fall above AMBERR (decision to major-
AMEND); hence, the estimate will fall into AMBERG or
GREEN (signifying a decision to minor-AMEND or GO,
respectively). The importance of adequately powering
the pilot trial to address a feasibility criterion can be
simply illustrated. For example, if we take RUL as 50%
and GLL as 75% but with two different sample sizes of n
= 25 and n = 50; the former would have 77.5% power of
rejecting RED on the basis of a 1-sided 5% alpha level
whereas the larger sample size would have 97.8% power
of rejecting RED. So, if GLL holds true, there would be
20% higher probability of rejecting the null and being in
the AMBERG/GREEN zone for the larger sample giving
an increased chance of progressing to the main trial. It
will be necessary to carry out the hypothesis test for the
extended 4-tier approach if the observed statistic (E) falls
in the AMBER zone to determine statistical significance
or not, which will inform whether the result falls into
the ‘minor’ or ‘major’ AMBER sub-zones.
We provide recommended sample sizes within a look-
up grid relating to perceived likely progression cut-
points to aid quick access and retrievable sample sizes
for researchers. For a likely set difference in proportions
between hypothesised null and alternative parameters of
0.15 to 0.25 when α = 0.05 and β = 0.1 the correspond-
ing total sample size requirements for the approach of
normal approximation with continuity correction take
the range of 33 to 100 (median 56) [similarly these are
33–98 (median 54) for the binomial exact method].
Note, for treatment fidelity/adherence/compliance par-
ticularly, the marginal difference could be higher, e.g. ≥
25%, since in most situations we would anticipate and
hope to attain a high value for the outcome whilst being
prepared to make necessary changes within a wide inter-
val of below par values (and providing the value is not
unacceptably low). As this relates to an arm-specific ob-
jective (relating to evaluation of the intervention only),
then a usual 1:1 pilot will require twice the size; hence,
the arm-specific sample size powered for detecting a ≥
25% difference from the null would be about 34 (or
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lower)—as depicted from our illustration (Table 4 (ii),
equating to n ≤ 68 overall for a 1:1 pilot; intervention
and control arms). Hence, we expect that typical pilot
sizes of around 30–40 randomised per arm [16] would
likely fit with the proposed methodology within this
manuscript (the number needed for screening being ex-
trapolated upward of this figure) but if a smaller mar-
ginal difference (e.g. ≤ 15%) is to be tested then these
sample sizes may fall short. We stress that the overall re-
quired sample size needs to be carefully considered and
determined in line with the hypothesis testing approach
across all criteria ensuring sufficiently high power. In
our paper, we have made recommendations regarding
various sample sizes based on both the normal approxi-
mation (with continuity correction) and binomial exact
approaches; these are conservative compared to the Nor-
mal approximation (without continuity correction).
Importantly, the methodology outlines the necessary
multi-criterion approach to the evaluation of pilot and
feasibility studies. If all progression criteria are perform-
ing as well as anticipated (highlighting ‘GO’ according to
all criteria), then the recommendation of the pilot/feasi-
bility study is that all criteria meet their desired levels
with no need for adjustment and the main trial can
proceed without amendment. However, if the worst sig-
nal (across all measured criteria) is an AMBER signal,
then adjustment will be required against those criteria
that fall within that signal. Consequently, there is the
possibility that the criteria may need subsequent re-
assessment to re-evaluate processes in line with updated
performance for the criteria in question. If one or more
of the feasibility statistics fall within the RED zone then
this signals ‘STOP’ and concludes that a main trial is not
feasible based on those criteria. This approach to collect-
ively appraising progression based on the results of all
feasibility outcomes assessed against their criteria will be
conservative as the power of the collective will be lower
than the individual power of the separate tests; hence, it
is recommended that the power of the individual tests is
set high enough (for example, 90–95%) to ensure the
collective power is high enough (e.g. at least 70 or 80%)
to detect true ‘GO’ signals across all the feasibility
criteria.
In this article, we also expand the possibilities for pro-
gression criterion and hypothesis testing where the
AMBER zone is sub-divided arbitrarily based on the sig-
nificance of the p value. This may work well when the
AMBER zone has a wide range and is intended to pro-
vide a useful and workable indication of the level of
amendment (‘minor’ (non-substantive) or ‘major’ (sub-
stantive)) required to progress to the main trial. Exam-
ples of substantial amendments include study re-design
with possible re-appraisal and change of statistical pa-
rameters, inclusion of several additional sites, adding
further data recruitment methods, significant reconfigur-
ation of exclusions, major change to the method of de-
livery of trial intervention to ensure enhanced treatment
fidelity/adherence, enhanced measures to systematically
ensure greater patient compliance with allocated treat-
ment, additional mode(s) of collecting and retrieving
data (e.g. use of electronic data collection methods in
addition to postal questionnaires). Minor amendments
include small changes to the protocol and methodology,
e.g. addition of one or two sites for attaining a slightly
higher recruitment rate, use of occasional reminders in
regard to treatment protocol and adding a further re-
minder process for boosting follow up. For the most
likely parametrisation of α = 0.05/β = 0.1, the AMBER
zone division will be roughly at the midpoint. However,
researchers can choose this point (the major/minor cut-
point) based on decisive arguments around how major
and minor amendments would align to the outcome in
question. This should be factored within the process of
sample size determination for the pilot. In this regard, a
smaller sample size will move AC upwards (due to in-
creased standard error/reduced precision) and hence in-
crease the size of the AMBERR zone in relation to
AMBERG (whereas a larger sample size will shift AC
downwards and do the opposite, increasing the ratio of
AMBERG:AMBERR). From Table 1, for smaller sample
sizes (related to 80% power) the AMBERR zone makes
up 56–69% of the total amber zone across presented sce-
narios, whereas this falls to 47–61% for samples (related
to 90% power) and 41–56% for larger samples (related
to 95% power) for the same scenarios. Beyond our pro-
posed 4-tier approach, other ways of providing an indi-
cation of level of amendment could include evaluation
and review of the point and interval estimates or by
evaluating posterior probabilities via a Bayesian ap-
proach [14, 32].
The methodology illustrated here focuses on feasibility
outcomes presented as percentages/proportions, which
is likely to be the most common form for progression
criteria under consideration. However, the steps that
have been introduced can be readily adapted to any
feasibility outcomes taking a numerical format, e.g. rate
of recruitment per month per centre, count of centres
taking part in the study. Also, we point out that in the
examples presented in the paper (recruitment, treatment
fidelity and percent follow-up), high proportions are ac-
ceptable and low ones not. This would not be true for,
say, adverse events where a reverse scale is required.
Biased sample estimates are a concern as they may re-
sult in a wrong decision being made. This systematic
error is over-and-above the possibility of an erroneous
decision being made on the basis of sampling error; the
latter may be reduced through an increased pilot sample
size. Any positive bias will inflate/overestimate the
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feasibility sample estimate in favour of progressing
whereas a negative bias will deflate/underestimate it to-
wards the null and stopping. Both are problematic for op-
posite reasons; for example, the former may inform
researchers that the main trial can ‘GO’ ahead when in
fact it will struggle to meet key feasibility targets, whereas
the latter may caution against progression when in reality
the feasibility targets of a main trial would be met. For ex-
ample, in regard to the choice of centres (and hence prac-
titioners and participants), a common concern is that the
selection of feasibility trial centres might not be a fair and
representative sample of the ‘population’ of centres to be
used for the main trial. It may be that the host centre
(likely used in pilot studies) recruits far better than others
(positive bias), thus exaggerating the signal to progress
and subsequent recruitment to the main trial. Beets et al.
[33] ‘define “risk of generalizability biases” as the degree to
which features of the intervention and sample in the pilot
study are NOT scalable or generalizable to the next stage
of testing in a larger, efficacy/effectiveness trial … whether
aspects like who delivers an intervention, to whom it is de-
livered, or the intensity and duration of the intervention
during the pilot study are sustained in the larger, efficacy/
effectiveness trial.’ As in other types of studies, safeguards
regarding bias should be addressed through appropriate
pilot study design and conduct.
Issues relating to progression criteria for internal pilots
may be different to those for external pilots and non-
randomised feasibility studies. The consequence of a ‘stop’
within an internal pilot may be more serious for stake-
holders (researchers, funders, patients) as it would bring
an end to the planned continuation into the main trial
phase, whereas there would be less at stake for a negative
external pilot. By contrast, the consequence of a ‘GO’ sig-
nal may work the other way with a clear and immediate
gain for the internal pilot whereas for an external pilot,
the researchers would still need to apply and get the ne-
cessary funding and approvals to undertake an intended
main trial. The chances of falling into the different traffic
light zones are likely to be quite different between the two
designs. Possibly external pilot and feasibility studies are
more likely to have estimates falling in and around the
RED zone than for internal pilots, reflecting the greater
uncertainty in the processes for the former and greater
confidence in the mechanisms for trial delivery for the lat-
ter. However, to counter this, there are often large chal-
lenges with recruitment within internal pilot studies
where the target population is usually spread over more
diverse sites than may be expected for an external pilot.
Despite this possible imbalance, the interpretation of zonal
indications remains consistent for external and internal
pilot studies. As such, our focus with regard to the recom-
mendations in this article are aligned to requirements for
external pilots, though application of this methodology to
a degree may similarly hold for internal pilots (and further,
to non-randomised studies that can include progression
criteria—including longitudinal observational cohorts with
the omission of the treatment fidelity criterion).
Conclusions
We propose a novel framework that provides a paradigm
shift towards formally testing feasibility progression cri-
teria in pilot and feasibility studies. The outlined ap-
proach ensures rigorous and transparent reporting in
line with CONSORT recommendations for evaluation of
STOP-AMEND-GO criteria and presents clear progres-
sion sign-posting which should help decision-making
and inform stakeholders. Targeted progression criteria
are focused on recommended pilot and feasibility objec-
tives, particularly recruitment uptake, treatment fidelity
and participant retention, and these criteria guide the
methodology for sample size derivation and statistical
testing. This methodology is intended to provide a more
definitive and rounded structure to pilot and feasibility
design and evaluation than currently exists. Sample size
recommendations will be dependent on the nature and
cut-points for multiple key pre-defined progression cri-
teria and should ensure a sufficient sample size for other
feasibility outcomes such as review of the precision of
clinical parameters to better inform main trial size.
Appendix
Mathematical formulae for derivation of sample size
The required sample size may be derived using normal
approximation to binary response data—using a continu-
ity correction, via Fleiss et al. [26] if the convention of
np > 5 and n(1 − p) > 5 holds true:
n ¼ z1 − ∝
ffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffi




GLL 1 −GLLð Þ
p
GLL − RULð Þ
 !2
þ 1
GLL − RULj j
where RUL = upper limit of RED zone; GLL = lower limit
of GREEN zone; z1−α = one-sided statistical significance
level (type I error probability); z1−β = beta (type II error
probability)
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Abbreviations
Alpha (α): Significance level (Type I error probability); AMBERG: AMBER sub-
zone split adjacent to the GREEN zone (within 4-tiered approach);
AMBERR: AMBER sub-zone split adjacent to the RED zone (within 4-tiered ap-
proach); AC: AMBER-statistical significance threshold (within the AMBER zone)
where an observed estimate below the cut-point will result in a non-
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significant result (p ≥ 0.05) and figures at or above the cut-point will be sig-
nificant (p < 0.05); AC%: AC expressed as a percentage of the sample size;
Beta (β): Type II error probability; E: Estimate of feasibility outcome; ε: True
feasibility parameter; GLL: Lower Limit of GREEN zone; n: Sample size (ns =
number of patients screened; nr = number of patients randomised; ni = number
of patients randomised to the intervention arm only); Power = 1-Beta: (1 – Type II
error probability); RUL: Upper Limit of RED zone
Acknowledgements
We thank Professor Julius Sim, Dr Ivonne Solis-Trapala, Dr Elaine Nicholls and
Marko Raseta for their feedback on the initial study abstract.
Authors’ contributions
ML and CJS conceived the original methodological framework for the paper.
ML prepared draft manuscripts. KB and GMcC provided examples and
illustrations. All authors contributed to the writing and provided feedback on
drafts and steer and suggestions for article updating. All authors read and
approved the final manuscript.
Funding
KB was supported by a UK 2017 NIHR Research Methods Fellowship Award
(ref RM-FI-2017-08-006).
Availability of data and materials
Not applicable.





The authors declare that they have no competing interests.
Author details
1Biostatistics Group, School of Medicine, Keele University, Room 1.111, David
Weatherall Building, Keele, Staffordshire ST5 5BG, UK. 2Keele Clinical Trials
Unit, Keele University, Keele, Staffordshire, UK. 3Centre for Biostatistics, School
of Health Sciences, University of Manchester, Manchester, Staffordshire, UK.
Received: 23 April 2020 Accepted: 7 January 2021
References
1. Lancaster GA, Dodd S, Williamson PR. Design and analysis of pilot studies:
recommendations for good practice. J Eval Clin Pract. 2004;10(2):307–12.
2. Eldridge SM, Chan CL, Campbell MJ, Bond CM, Hopewell S, Thabane L, et al.
CONSORT 2010 statement: extension to randomised pilot and feasibility
trials. Pilot Feasibility Stud. 2016;2:64.
3. McDonald AM, Knight RC, Campbell MK, Entwistle VA, Grant AM, Cook JA,
et al. What influences recruitment to randomised controlled trials? A review
of trials funded by two UK funding agencies. Trials. 2006;7:9.
4. Sully BG, Julious SA, Nicholl J. A reinvestigation of recruitment to
randomised, controlled, multicenter trials: a review of trials funded by two
UK funding agencies. Trials. 2013;14:166.
5. Walters SJ, Bonacho Dos Anjos Henriques-Cadby I, Bortolami O, Flight L,
Hind D, Jacques RM, et al. Recruitment and retention of participants in
randomised controlled trials: a review of trials funded and published by the
United Kingdom Health Technology Assessment Programme. BMJ Open.
2017;7(3):e015276.
6. Julious SA. Sample size of 12 per group rule of thumb for a pilot study.
Pharm Stat. 2005;4:287–91.
7. Thabane L, Ma J, Chu R, Cheng J, Ismaila A, Rios LP, et al. A tutorial on pilot
studies: the what, why and how. BMC Med Res Methodol. 2010;10:1.
8. Browne RH. On the use of a pilot sample for sample size determination.
Stat Med. 1995;14:1933–40.
9. Hertzog MA. Considerations in determining sample size for pilot studies. Res
Nurs Health. 2008;31(2):180–91.
10. Sim J, Lewis M. The size of a pilot study for a clinical trial should be
calculated in relation to considerations of precision and efficiency. J Clin
Epidemiol. 2012;65(3):301–8.
11. Whitehead AL, Julious SA, Cooper CL, Campbell MJ. Estimating the sample
size for a pilot randomised trial to minimise the overall trial sample size for
the external pilot and main trial for a continuous outcome variable. Stat
Methods Med Res. 2016;25(3):1057–73.
12. Teare MD, Dimairo M, Shephard N, Hayman A, Whitehead A, Walters SJ.
Sample size requirements to estimate key design parameters from external
pilot randomised controlled trials: a simulation study. Trials. 2014;15:264.
13. Cocks K, Torgerson DJ. Sample size calculations for pilot randomized trials: a
confidence interval approach. J Clin Epidemiol. 2013;66(2):197–201.
14. Lee EC, Whitehead AL, Jacques RM, Julious SA. The statistical interpretation
of pilot trials: should significance thresholds be reconsidered? BMC Med Res
Methodol. 2014;14:41.
15. Johanson GA, Brooks GP. Initial scale development: sample size for pilot
studies. Edu Psychol Measurement. 2010;70(3):394–400.
16. Billingham SA, Whitehead AL, Julious SA. An audit of sample sizes for pilot
and feasibility trials being undertaken in the United Kingdom registered in
the United Kingdom Clinical Research Network database. BMC Med Res
Methodol. 2013;13:104.
17. Herbert E, Julious SA, Goodacre S. Progression criteria in trials with an
internal pilot: an audit of publicly funded randomised controlled trials. Trials.
2019;20(1):493.
18. Avery KN, Williamson PR, Gamble C, O’Connell Francischetto E, Metcalfe C,
Davidson P, et al. Informing efficient randomised controlled trials:
exploration of challenges in developing progression criteria for internal pilot
studies. BMJ Open. 2017;7(2):e013537.
19. Arain M, Campbell MJ, Cooper CL, Lancaster GA. What is a pilot or feasibility
study? A review of current practice and editorial policy. BMC Med Res
Methodol. 2010;10:67.
20. Leon AC, Davis LL, Kraemer HC. The role and interpretation of pilot studies
in clinical research. J Psychiatr Res. 2011;45(5):626–9.
21. Horne E, Lancaster GA, Matson R, Cooper A, Ness A, Leary S. Pilot trials in
physical activity journals: a review of reporting and editorial policy. Pilot
Feasibility Stud. 2018;4:125.
22. Wilson DT, Walwyn RE, Brown J, Farrin AJ, Brown SR. Statistical challenges in
assessing potential efficacy of complex interventions in pilot or feasibility
studies. Stat Methods Med Res. 2016;25(3):997–1009.
23. Sim J. Should treatment effects be estimated in pilot and feasibility studies?
Pilot Feasibility Stud. 2019;5:107.
24. Moore CG, Carter RE, Nietert PJ, Stewart PW. Recommendations for planning
pilot studies in clinical and translational research. Clin Transl Sci. 2011;4(5):332–7.
25. Schoenfeld D. Statistical considerations for pilot studies. Int J Radiat Oncol
Biol Phys. 1980;6(3):371–4.
26. Fleiss JL, Levin B, Paik MC. Statistical methods for rates and proportions,
Third Edition. New York: John Wiley & Sons; 2003. p. 32.
27. Faul F, Erdfelder E, Lang AG, Buchner A. G*Power 3: A flexible statistical
power analysis program for the social, behavioral, and biomedical sciences.
Behav Res Methods. 2007;39:175–91.
28. Julious SA. Pilot studies in clinical research. Stat Methods Med Res. 2016;
25(3):995–6.
29. Lancaster GA. Pilot and feasibility studies come of age! Pilot Feasibility Stud.
2015;1(1):1.
30. Charlesworth G, Burnell K, Hoe J, Orrell M, Russell I. Acceptance checklist for
clinical effectiveness pilot trials: a systematic approach. BMC Med Res
Methodol. 2013;13:78.
31. Blatch-Jones AJ, Pek W, Kirkpatrick E, Ashton-Key M. Role of feasibility and
pilot studies in randomised controlled trials: a cross-sectional study. BMJ
Open. 2018;8(9):e022233.
32. Willan AR, Thabane L. Bayesian methods for pilot studies. Clin Trials 2020;
17(4):414-9.
33. Beets MW, Weaver RG, Ioannidis JPA, Geraci M, Brazendale K, Decker L, et al.
Identification and evaluation of risk of generalizability biases in pilot versus
efficacy/effectiveness trials: a systematic review and meta-analysis. Int J
Behav Nutr Phys Act. 2020;17:19.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Lewis et al. Pilot and Feasibility Studies            (2021) 7:40 Page 14 of 14
